News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Lori Dahncke, BSN, RN

Advertisement

Articles by Lori Dahncke, BSN, RN

A Guide to Nursing Discharge of Patients Receiving CAR T-Cell Therapy

ByKara Yannotti, MMH, RN, Elizabeth McCarthy, MSN, RN, Sabrina Kdiry, BSN, RN,Lori Dahncke, BSN, RN
June 29th 2018

Standardized and focused education for patients receiving CAR T-cell therapy and their caregivers should be part of discharge procedures.

Advertisement

Latest Updated Articles

  • A Guide to Nursing Discharge of Patients Receiving CAR T-Cell Therapy
    A Guide to Nursing Discharge of Patients Receiving CAR T-Cell Therapy

    Published: June 29th 2018 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Improving Access to Supportive Care on an Organizational Level, With Korie Bigbee

2

Managing Acute and Late Adverse Effects of Breast Cancer Radiation

3

The “Owners” and “Managers” in the Peer-to-Peer Process: What an APP Should Know

4

An NP’s Perspective: Supporting Derm Toxicities in Breast Cancer as a Team

5

Comorbidities, Quality of Life, Efficacy, and Safety in Expanding SubQ Use

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us